News Topic - Nasdaq
Articles 81 - 90 of most recent articles
U.S. stocks decline after dip in leading economic indicators
NEW YORK (MarketWatch) -- U.S. stocks pared gains after the Conference Board said its index of leading economic indicators fell 0.1% in June. Up more than 40 points before the Conference Board's report, the Dow Jones Industrial Average was up 10.91 points at 11,507.48. The S&P 500 rose 2.26 points to 1,263.04, while the Nasdaq Composite added 5.59 points to 2,288.37.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MarketWatch.com – Jul 21, 2008 2:09 PM [GMT] ¦ comment?
found in Business: Markets
NEW YORK (MarketWatch) -- U.S. stocks pared gains after the Conference Board said its index of leading economic indicators fell 0.1% in June. Up more than 40 points before the Conference Board's report, the Dow Jones Industrial Average was up 10.91 points at 11,507.48. The S&P 500 rose 2.26 points to 1,263.04, while the Nasdaq Composite added 5.59 points to 2,288.37.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MarketWatch.com – Jul 21, 2008 2:09 PM [GMT] ¦ comment?
found in Business: Markets
Tech stocks mostly rise; Yahoo down as Icahn joins board
SAN FRANCISCO (MarketWatch) -- Technology stocks largely rose in early trading Monday as the sector's action was highlighted by a peace deal between Yahoo Inc. and activist shareholder Carl Icahn. Yahoo will add Icahn and two other Icahn associates to the company's board, expanding its board of directors to 11 members. Investors weren't too thrilled by the deal, as Yahoo shares fell 60 cents, or 2.7%, to $21.89. Still, the tech-heavy Nasdaq Composite Index rose 12 points to 2,294 with gains coming from Apple Inc. , Microsoft Corp. and Intel Corp. .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MarketWatch.com – Jul 21, 2008 1:52 PM [GMT] ¦ comment?
found in Business: Markets
SAN FRANCISCO (MarketWatch) -- Technology stocks largely rose in early trading Monday as the sector's action was highlighted by a peace deal between Yahoo Inc. and activist shareholder Carl Icahn. Yahoo will add Icahn and two other Icahn associates to the company's board, expanding its board of directors to 11 members. Investors weren't too thrilled by the deal, as Yahoo shares fell 60 cents, or 2.7%, to $21.89. Still, the tech-heavy Nasdaq Composite Index rose 12 points to 2,294 with gains coming from Apple Inc. , Microsoft Corp. and Intel Corp. .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MarketWatch.com – Jul 21, 2008 1:52 PM [GMT] ¦ comment?
found in Business: Markets
Triple Crown Media, Inc. Announces Nasdaq Staff Determination Letter
Read full story for latest details.
PR Newswire – Jul 21, 2008 1:37 PM [GMT] ¦ comment?
found in Top Stories: Press Releases
Read full story for latest details.
PR Newswire – Jul 21, 2008 1:37 PM [GMT] ¦ comment?
found in Top Stories: Press Releases
U.S. stocks begin ahead on BofA results and M&A activity
NEW YORK (MarketWatch) - U.S. stocks on Monday started higher after Bank of America Corp.'s earnings topped forecasts, giving a lift to financial shares, and Roche Holding AG offered $43.7 billion for the piece of Genentrech Inc. that it doesn't already own. The Dow Jones Industrial Average gained 36.48 points to 11,533.05. The S&P 500 rose 3.86 points to 1,264.53, while the Nasdaq Composite advanced 5.92 points to 2,288.70.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MarketWatch.com – Jul 21, 2008 1:36 PM [GMT] ¦ comment?
found in Business: Markets
NEW YORK (MarketWatch) - U.S. stocks on Monday started higher after Bank of America Corp.'s earnings topped forecasts, giving a lift to financial shares, and Roche Holding AG offered $43.7 billion for the piece of Genentrech Inc. that it doesn't already own. The Dow Jones Industrial Average gained 36.48 points to 11,533.05. The S&P 500 rose 3.86 points to 1,264.53, while the Nasdaq Composite advanced 5.92 points to 2,288.70.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MarketWatch.com – Jul 21, 2008 1:36 PM [GMT] ¦ comment?
found in Business: Markets
TSA Expands Pilot Testing of AS&E's Privacy Enhanced SmartCheck Personnel Screening System to JFK International Airport
BILLERICA, Mass.--(BUSINESS WIRE)--American Science and Engineering, Inc. (NASDAQ: ASEI) (AS&E
Business Wire – Jul 21, 2008 1:00 PM [GMT] ¦ comment?
found in Business
BILLERICA, Mass.--(BUSINESS WIRE)--American Science and Engineering, Inc. (NASDAQ: ASEI) (AS&E
Business Wire – Jul 21, 2008 1:00 PM [GMT] ¦ comment?
found in Business
Futures point to weak Wall St. start; results eyedReuters - (REUTERS) U.S. index futures point to a weak start on Wall Street. Futures for the S&P 500, for the Dow Jones industrial average and Nasdaq are down 0.3 percent.
Yahoo! – Jul 21, 2008 09:39 AM [GMT] ¦ comment?
found in World: Europe
FDA Grants Clearance For Celera's ViroSeq® HIV-1 Genotyping System Software V2.8
Celera (NASDAQ:CRA) announced that it has received marketing clearance from the U.S. Food and Drug Administration for its 510(k) submission of the ViroSeq HIV-1 Genotyping System Software v2.8. The ViroSeq HIV-1 Genotyping™ System is designed to detect mutations in the HIV-1 viral genome that confer drug resistance, and as such, is used as an aid in monitoring and treating HIV-1 infections.
Medical News Today – Jul 21, 2008 09:00 AM [GMT] ¦ comment?
found in Health: AIDS - HIV
Celera (NASDAQ:CRA) announced that it has received marketing clearance from the U.S. Food and Drug Administration for its 510(k) submission of the ViroSeq HIV-1 Genotyping System Software v2.8. The ViroSeq HIV-1 Genotyping™ System is designed to detect mutations in the HIV-1 viral genome that confer drug resistance, and as such, is used as an aid in monitoring and treating HIV-1 infections.
Medical News Today – Jul 21, 2008 09:00 AM [GMT] ¦ comment?
found in Health: AIDS - HIV
Introgen To Present ADVEXIN Phase 3 Study Results At American Association For Cancer Research's Cancer Clinical Trials
Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA.
Medical News Today – Jul 21, 2008 09:00 AM [GMT] ¦ comment?
found in Health: Cancer
Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA.
Medical News Today – Jul 21, 2008 09:00 AM [GMT] ¦ comment?
found in Health: Cancer
Armando Iannucci: Welcome to the brave new world of Murdoch
In the annals of business acumen, no single act of commercial chutzpah can surpass the company manoeuvres carried out by Rupert Murdoch over the period 2010 to 2014. To assess just how revolutionary, how completely beyond the reach of what any human individual had yet achieved in more than 30 millenniums of civilisation his actions were, it is useful to note that prior to the year 2010 the figure of Rupert Murdoch was one respected but never adored by people of influence who considered themselves his peers. True, he was the world's most successful and influential publisher. Now in his mid-70s, he showed no sign of loosening the reins of power he held so firmly in his two gnarled hands. But there was talk. What would happen when his mental powers started to fade? Why had he not planned any orderly succession, whether to someone in his family or to a trusted colleague? And how sure was his touch, now that the print media as well as film and television were fast looking obsolete against the rise of the digital citizenship. In short, was he beginning to think he was both infallible and immortal? And so, when Rupert Murdoch called a meeting of his entire executive committee on 12 January 2014, many were expecting something momentous. At the very least, the demand forming among the mass of executives and expensively shirted dogsbodies shortly before the great man entered the room was that, unless he laid before them a very clear pattern of succession, they would resign en masse and thus, surely, cause a collapse in his parent company. In one way at least, he met their demands. The man, the figure, the legend, entered the room and asked for the lights to be dimmed. He began his powerpoint presentation, flashing a quick succession of slides and charts before this, his most important viewing audience. Corporate declarations tumbled out of him. 'I have purchased a 59 per cent stake in Sun Microsystems'; 'News Corp.has consolidated its share position on the boards of 14 South Asian cellphone networks'; 'I have merged Transmutual Holdings with our southern American division to form a new parent group for all terrestrial entertainment networks.' On and on they spurted. '... taking all the European subsidiary companies and merging them with a new North African web presence ...' No one knew where this was heading, but neither had anyone seen Murdoch so energised since his last marriage. '... promoting the chairman of Digital Investment to the new post of vice-president Corporate Sustenance ...' And the phrases became stranger, introducing concepts and references that few in the room had heard before. '... executive director of the Mother-Board...'; '... a billion-dollar investment in skin and infrastructure ...'; '... company cells multiply exponentially ...' And in the end it came: the announcement that would transform the world. 'And so, ladies and gentlemen, I have thrown into action a complicated sequence of company mergers and buy-outs, and a logarithmically positioned series of investments, that now mean all my main subsidiary companies form a unique pattern across the globe. It's a pattern so complex that no other sequence of values come close to it, save for the integers of DNA. 'And that is no accident. For I have arranged my companies in the one precise global sequence that will set the conditions right for the birth of life itself. My company is now so complex, so intelligent, so diverse and yet so intricately controlled that it has acquired all the first properties of a living organism. My company has become a life-form! 'Primitive at first, it will need nurturing from a top team of hand-picked executives, but within a year it will think for itself, feed itself, learn, defend and, if necessary, attack. Behold, I have created a living company. I have created Child International!' At this, the magnificent man raised his left arm and the curtains behind him parted. On a large screen dominating the chamber could be seen a complex web of numbers, flickering and scrolling across the plasma. As the audience stared up at the figures, the pattern of digits seemed to alter slightly, as if winking back. 'That,' said Murdoch 'is Child International recognising your presence and, within the space of a microsecond, calculating the amount of shares it needs to buy and sell on Nasdaq in order to make it look as if it's blinking.' The men and women in the room gasped in surprise and a little fear. 'What were the consequences of that action?' asked one middle-aged executive known for his good personnel skills. 'Our share value went down by 0.04 per cent and we had to lay off 1,500 workers in China.' The people groaned. Immediately, the screen flickered and the numbers on it formed the shape of a smile. A package arrived at the door to the room and, when it was opened, a small cube leapt out making the noise: 'Only joking!' 'You needn't worry,' said Murdoch. 'Child International was able, in a nano-instant, to pour just the right amount of financial investment into technological development that it was able, within 12 seconds of its last action, to launch on to the market a new electronic one-inch cube that can make more than 13,000 entertaining remarks. The Chirpy-Blok has already made us $4bn.' There was silence in the room. The numbers on the screen stared accusingly at the people round the table, who each knew in their hearts what had to be done. One by one, the executives tendered their resignation, knowing that Murdoch had indeed appointed his successor and it wasn't going to be human. So the living company, Child International, carried on trading successfully on its own for the next 24 years until, in 2038, it was bought by the Chinese and, two days later, committed suicide.Related StoriesUK fails to bar internet access to child pornHi-tech is turning us all into time-wastersFamily videotape treasures at riskCheck your connections to avoid a shocking holidayMartin Love discusses the Volvo S80
The Guardian – Jul 19, 2008 11:02 PM [GMT] ¦ comment?
found in Technology
In the annals of business acumen, no single act of commercial chutzpah can surpass the company manoeuvres carried out by Rupert Murdoch over the period 2010 to 2014. To assess just how revolutionary, how completely beyond the reach of what any human individual had yet achieved in more than 30 millenniums of civilisation his actions were, it is useful to note that prior to the year 2010 the figure of Rupert Murdoch was one respected but never adored by people of influence who considered themselves his peers. True, he was the world's most successful and influential publisher. Now in his mid-70s, he showed no sign of loosening the reins of power he held so firmly in his two gnarled hands. But there was talk. What would happen when his mental powers started to fade? Why had he not planned any orderly succession, whether to someone in his family or to a trusted colleague? And how sure was his touch, now that the print media as well as film and television were fast looking obsolete against the rise of the digital citizenship. In short, was he beginning to think he was both infallible and immortal? And so, when Rupert Murdoch called a meeting of his entire executive committee on 12 January 2014, many were expecting something momentous. At the very least, the demand forming among the mass of executives and expensively shirted dogsbodies shortly before the great man entered the room was that, unless he laid before them a very clear pattern of succession, they would resign en masse and thus, surely, cause a collapse in his parent company. In one way at least, he met their demands. The man, the figure, the legend, entered the room and asked for the lights to be dimmed. He began his powerpoint presentation, flashing a quick succession of slides and charts before this, his most important viewing audience. Corporate declarations tumbled out of him. 'I have purchased a 59 per cent stake in Sun Microsystems'; 'News Corp.has consolidated its share position on the boards of 14 South Asian cellphone networks'; 'I have merged Transmutual Holdings with our southern American division to form a new parent group for all terrestrial entertainment networks.' On and on they spurted. '... taking all the European subsidiary companies and merging them with a new North African web presence ...' No one knew where this was heading, but neither had anyone seen Murdoch so energised since his last marriage. '... promoting the chairman of Digital Investment to the new post of vice-president Corporate Sustenance ...' And the phrases became stranger, introducing concepts and references that few in the room had heard before. '... executive director of the Mother-Board...'; '... a billion-dollar investment in skin and infrastructure ...'; '... company cells multiply exponentially ...' And in the end it came: the announcement that would transform the world. 'And so, ladies and gentlemen, I have thrown into action a complicated sequence of company mergers and buy-outs, and a logarithmically positioned series of investments, that now mean all my main subsidiary companies form a unique pattern across the globe. It's a pattern so complex that no other sequence of values come close to it, save for the integers of DNA. 'And that is no accident. For I have arranged my companies in the one precise global sequence that will set the conditions right for the birth of life itself. My company is now so complex, so intelligent, so diverse and yet so intricately controlled that it has acquired all the first properties of a living organism. My company has become a life-form! 'Primitive at first, it will need nurturing from a top team of hand-picked executives, but within a year it will think for itself, feed itself, learn, defend and, if necessary, attack. Behold, I have created a living company. I have created Child International!' At this, the magnificent man raised his left arm and the curtains behind him parted. On a large screen dominating the chamber could be seen a complex web of numbers, flickering and scrolling across the plasma. As the audience stared up at the figures, the pattern of digits seemed to alter slightly, as if winking back. 'That,' said Murdoch 'is Child International recognising your presence and, within the space of a microsecond, calculating the amount of shares it needs to buy and sell on Nasdaq in order to make it look as if it's blinking.' The men and women in the room gasped in surprise and a little fear. 'What were the consequences of that action?' asked one middle-aged executive known for his good personnel skills. 'Our share value went down by 0.04 per cent and we had to lay off 1,500 workers in China.' The people groaned. Immediately, the screen flickered and the numbers on it formed the shape of a smile. A package arrived at the door to the room and, when it was opened, a small cube leapt out making the noise: 'Only joking!' 'You needn't worry,' said Murdoch. 'Child International was able, in a nano-instant, to pour just the right amount of financial investment into technological development that it was able, within 12 seconds of its last action, to launch on to the market a new electronic one-inch cube that can make more than 13,000 entertaining remarks. The Chirpy-Blok has already made us $4bn.' There was silence in the room. The numbers on the screen stared accusingly at the people round the table, who each knew in their hearts what had to be done. One by one, the executives tendered their resignation, knowing that Murdoch had indeed appointed his successor and it wasn't going to be human. So the living company, Child International, carried on trading successfully on its own for the next 24 years until, in 2038, it was bought by the Chinese and, two days later, committed suicide.Related StoriesUK fails to bar internet access to child pornHi-tech is turning us all into time-wastersFamily videotape treasures at riskCheck your connections to avoid a shocking holidayMartin Love discusses the Volvo S80
The Guardian – Jul 19, 2008 11:02 PM [GMT] ¦ comment?
found in Technology
Start Of Phase II Clinical Trial With TRIOLEX™ (HE3286) In Type-2 Diabetes Patients; Sites Expanded To Accelerate Enrollment
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, announced that it has commenced a Phase II clinical trial with its oral drug candidate TRIOLEX™ (HE3286) in type 2 diabetes patients, and that it is expanding the number of clinical sites to accelerate enrollment.
Medical News Today – Jul 19, 2008 08:00 AM [GMT] ¦ comment?
found in Health: Diabetes
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, announced that it has commenced a Phase II clinical trial with its oral drug candidate TRIOLEX™ (HE3286) in type 2 diabetes patients, and that it is expanding the number of clinical sites to accelerate enrollment.
Medical News Today – Jul 19, 2008 08:00 AM [GMT] ¦ comment?
found in Health: Diabetes